Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

CompletedOBSERVATIONAL

Enrollment

208

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

March 1, 2024

Study Completion Date

May 20, 2024

Conditions

Hepatocellular CarcinomaLenvatinib

Interventions

DRUG

Lenvatinib

Lenvatinib combined with hepatic arterial infusion chemotherapy and PD-1/PD-L1;

Trial Locations (1)

Cancer Center Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT06435013 - Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC | Biotech Hunter | Biotech Hunter